Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that CD19 + and not BCR::ABL1 status confers therapeutic sensitivity to Blinatumomab in patients with Acute Lymphoblastic Leukemia.
The Republic of Ireland's Health Service Executive (HSE) has approved blinatumomab for reimbursement as a monotherapy treatment option for the treatment of pediatric patients aged 1 year or older with high-risk first relapsed with Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukemia (ALL) as part of the consolidation therapy.
This statement is based on a regulatory approval from the Health Service Executive:
As monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukaemia (ALL) as part of the consolidation therapy.
Citation
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2024-01-16 | Van Allen lab | Adding HSE approvals for reimbursement to database |
| 2022-05-01 | Health Service Executive | Indication approved for reimbursement. |